Today: 9 June 2026

Roman Perkowski

Big Funds Boost GM Holdings, But Filings Show the Details

Big Funds Boost GM Holdings, But Filings Show the Details

National Pension Service raised its GM stake by 78.8% in Q4, buying 1.7 million shares, while Geode and Allstate also increased holdings, SEC filings show. GM last month reported Q1 revenue of $43.6 billion and lifted its 2026 EBIT-adjusted target by $500 million to $13.5–$15.5 billion. The company set an 18-cent dividend for June 18 and maintains a $6 billion buyback plan.
29 May 2026
·
Ondas Shares Jump on Drone Funding Talks and New Filings

Ondas Shares Jump on Drone Funding Talks and New Filings

Ondas shares closed at $13.25 after a surge in drone and defense-tech stocks Thursday, following reports of possible U.S. government funding for the sector. The company registered 2.7 million shares for resale tied to its $196.6 million Omnisys acquisition. First-quarter revenue rose to $50.1 million, up tenfold from a year earlier. Shareholders approved an increase in the stock incentive plan to 81 million shares.
29 May 2026
······
Red Cat Stock Sinks as Discounted $225 Million Sale Tests Drone Boom Thesis

Red Cat Jumps 32% on Drone Hype, Eyes Maritime Move

Red Cat shares rose 32% to $14.15 in after-hours trading Thursday, with over 77 million shares traded. The company announced its Blue Ops unit will begin full-rate production of the U.S.-built Variant 7 uncrewed surface vessel. Drone stocks rallied after reports of possible Trump administration funding for U.S. drone firms. Red Cat was not named in those talks but moved with the sector.
29 May 2026
··
1 … 4 5 6

Stock Market Today

  • J.M. Smucker Shares Rise After Earnings Beat Despite Sales Warning
    June 9, 2026, 10:05 AM EDT. J.M. Smucker shares rose 3.16% in pre-market trading after the company reported a 20% rise in adjusted earnings per share to $2.77, beating Wall Street estimates. The packaged-food firm grew net sales by 6% to $2.27 billion in Q4 but issued a cautionary note, forecasting a 3-4% decline in annual sales for fiscal 2027, below analysts' expectations of 1% growth. CEO Mark Smucker highlighted a focus on organic volume growth and profit improvement amid shifts in industry pricing strategies. Coffee sales drove quarterly results with a 12% retail sales increase but volume declines. The company flagged risks including consumer shifts to store brands, weight-loss drug impacts, and tariff fluctuations. Smucker's outlook balances lower sales with improved profitability.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Go toTop